… and other SSRIs
Oh, and also for the review into the MHRA that was recommended 3 years ago!
Early Day Motion 1056 by Jim Dobbin MP – SSRI ANTI-DEPRESSANTS
26.02.2008
That this House welcomes the Department of Health’s announcement to increase the provision of talking therapy for depression; notes Professor Irving Kirsch’s study of the manufacturer’s trials of the SSRI anti-depressants Prozac, Seroxat and Efexor and his conclusion that these drugs are not effective; notes that there is zero cost-effectiveness to drugs that do not work; further notes that large numbers of people are involuntary addicted to these drugs and suffer bizarre and severe side effects which leave them unable to work; calls upon the National Institute of Health and Clinical Excellence to review the approval of these drugs; calls upon the Government to provide withdrawal clinics for people addicted to prescribed drugs; further calls upon the Government to provide appropriate rehabilitation to bring these people back into the workforce; urges the Government to organise controlled withdrawal of these drugs from the market; and further urges the Government to investigate how the manufacturers and distributors obtained product licences and to implement the recommendations of the Fourth Report of the Health Committee, Session 2004-05, on the Influence of the Pharmaceutical Industry, HC42-1, including an independent review of the UK drug licensing authority the Medicines and Healthcare Products Regulatory Agency.
Signed by the following MPs:
And another EDM:
EDM 1041 by Paul Flynn
ANTI-DEPRESSANT DRUG TRIALS
26.02.2008
That this House welcomes the revelation under Freedom of Information of un-published trial reports on anti-depressants that prove they are no more effective than placebos for the great majority of patients; deplores the practice of pharmaceutical companies of suppressing publication of trials with negative results that has encouraged the over-prescription of drugs that have serious adverse side-effects; and calls for a re-appraisal of the efficacy of drug treatment for mild depression compared with the drug-free therapies of exercise and cognitive behaviour therapy.
